Install
Latest in Research & Evidence
Research & Evidence at a glance
The 10 latest articles on Research & Evidence come from 8 sources, published between Nov 12 and Nov 13. Most come from markets.businessinsider.com (3).
People in these stories: Chen (2), Zhang (2), Amir Heshmatpour (2)
Organizations: FDA (6), NDA (3), U.S. Food and Drug Administration (3), Federal Food (2), NeOnc Technologies Holdings (2), NTHI (2)
Places: MD (2), UK (2), DENVER (2), Australia (2)
Entresto may reduce atrial fibrillation recurrence after ablation in certain patients
American Heart Association Scientific Sessions ByErik Swain Fact checked byRichard Smith Purpose-built for physicians Learn more Read more Entresto may reduce atrial fibrillation recurrence after ablation in certain patients November 13, 2026 2 min read ByErik Swain Fact checked byRichard Smith Add topic…
Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial
9 November 2026 Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patients Announcement comes after a recent European Respiratory Journal viewpoint by Qureight…
Rezolute releases interim phase 3 results of ersodetug in tumor hyperinsulinism
Nov 13, 2026, 8:49 AM ETRezolute, Inc. (RZLT) StockBy: Jonathan Block, SA News Editorkoto_feja Rezolute (RZLT) said that preliminary data from its phase 3 upLIFT study of ersodetug in tumor hyperinsulinism found that 13 of 16 enrolled patients achieved at least a 50% reduction from baseline in glucose…
NeOnc granted Type B End-of-Phase meeting by FDA for intranasal NEO100
TipRanks Nov. 11, 2026, 08:05 AM NeOnc Technologies (NTHI) announced that the FDA has granted the company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma. The meeting is scheduled for…
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
PRESS RELEASE GlobeNewswire Nov. 11, 2026, 08:00 AM CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and…
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
PRESS RELEASE GlobeNewswire Nov. 11, 2026, 08:37 AM DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- (247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for…
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
Rhea-AI Impact (Very High) Rhea-AI Sentiment (Positive)How Sentiment works Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown…
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Recent Quotes My Watchlist Indicators Markets Stocks ETFs Tools Markets: Overview News Currencies International Treasuries OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in…
Personalized mobile health coaching reduces gestational diabetes among pregnant women
Top Health Categories ×Top Health Categories Personalized mobile health coaching reduces gestational diabetes among pregnant women if (g_displayableSlots.mobileTopLeaderboard) { pushDisplayAd(function() { googletag.display('div-gpt-mobile-top-leaderboard'); }); } UCD Research and InnovationNov 13 2026Reviewed A continuous, personalized mobile health (mHealth) coaching program can significantly reduce gestational diabetes…
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.